Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK's Pandemrix problems rumble on

This article was originally published in Scrip

Executive Summary

UK media reports suggesting that the British government is preparing to pay out £1m each to an alleged 60 patients who developed narcolepsy following administration of Pandemrix, have once again turned the spotlight onto the rare adverse event. GlaxoSmithKline – which produced Pandemrix – declined to comment on the latest reports but appears to have shifted slightly from its position a year ago that data were "insufficient" to assess the likelihood of a causal association between Pandemrix and narcolepsy (scripintelligence.com, 27 February 2013).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC024627

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel